Diurnal variation of plasma protease inhibitor concentrations

被引：18

作者：

Justesen, US ^{[1
]}

Pedersen, C

机构：

[1] Univ So Denmark, Inst Publ Hlth Clin Pharmacol, Odense, Denmark

[2] Odense Univ Hosp, Dept Infect Dis, DK-5000 Odense, Denmark

来源：

AIDS | 2002年 / 16卷 / 18期

关键词：

D O I：

10.1097/00002030-200212060-00019

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Diurnal variation in plasma concentrations of nelfinavir and ritonavir has previously been described. Plasma concentrations of 29 pharmacokinetic profiles with indinavir, amprenavir and saquinavir were evaluated, and a statistically significant median difference of 57.6% was found between morning and evening, with the morning C-through being higher than the evening C-through.Consequently, a change in dosing intervals might result in more balanced plasma protease inhibitor concentrations, thereby decreasing toxicity and the risk of virological failure.

引用

页码：2487 / 2489

页数：3

共 5 条

[1] AARNOUTSE R, 2001, 8 C RETR OPP INF CHI
[2] Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients
Baede-van Dijk, PA
Hugen, PWH
Verweij-van Wissen, CPWGM
Koopmans, PP
Burger, DM
Hekster, YA
[J]. AIDS, 2001, 15 (08) : 991 - 998
[3] BURGER DM, 2000, AIDS S4, V14, pP258
[4] The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring
Gatti, G
Di Biagio, A
Casazza, R
De Pascalis, C
Bassetti, M
Cruciani, M
Vella, S
Bassetti, D
[J]. AIDS, 1999, 13 (15) : 2083 - 2089
[5] Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
Hsu, A
Granneman, GR
Witt, G
Locke, C
Denissen, J
Molla, A
Valdes, J
Smith, J
Erdman, K
Lyons, N
Niu, P
Decourt, JP
Fourtillan, JB
Girault, J
Leonard, JM
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) : 898 - 905

← 1 →